Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.…
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals (NASDAQ: PHIO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 6 employees.
The shares were at 0.6560 USD on 20 November 2026, down 55.7% over 52 weeks. Its 52-week range is 0.6395 USD to 1.880 USD: the price is 65.1% below the high and 2.6% above the low.
Its market capitalisation is 7.84M USD.
Phio Pharmaceuticals reports return on equity of -43.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 10.61M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.